Induction of in vivo resistance against gemcitabine (dFdC, 2',2'-difluoro-deoxycytidine).
Ruiz van Haperen
V W
VW
Department Clinical Investigation, M. D. Anderson Cancer Center, Houston, Texas, USA.
Veerman
G
G
van Moorsel
C J
CJ
Peters
G J
GJ
D000818:Animals; D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use* / Q000633:toxicity*; D002460:Cell Line; D003110:Colonic Neoplasms / Q000188:drug therapy*; D003841:Deoxycytidine / Q000031:analogs & derivatives* / Q000627:therapeutic use / Q000633:toxicity; D003842:Deoxycytidine Kinase / Q000378:metabolism; D019008:Drug Resistance, Neoplasm; D007700:Kinetics; D051379:Mice; D008807:Mice, Inbred BALB C; D013937:Thymidine Kinase / Q000378:metabolism; D014407:Tumor Cells, Cultured; D000093542:Gemcitabine
D000964:Antimetabolites, Antineoplastic; D003841:Deoxycytidine; C105339:thymidine kinase 2; D013937:Thymidine Kinase; C092717:thymidine kinase 1; D003842:Deoxycytidine Kinase; D000093542:Gemcitabine